US Neurology Editorial Board member, Stewart Tepper (Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA), discusses the latest therapies in the management of headache.
- What are the current unmet needs in new therapies for headache? (0:04)
- What is the rationale for targeting calcitonin gene-related peptide (CGRP) in the management of headache disorders? (0:45)
- What anti-CGRP monoclonal antibodies are currently available for migraine prevention and how are they administered? (1:28)
- Which patients are most likely to respond to these therapies and in which patients should they not be used? (3:08)
- What is known about the short-term safety profile of these therapies? (4:12)
- What are the possible long-term side effects of anti-CGRP monoclonal antibodies? (5:21)
Grants for research (no personal compensation): Alder, Allergan, Amgen, ATI, Dr. Reddy’s, ElectroCore, eNeura, Neurolief, Scion Neurostim, Teva, Zosano.
Consultant and/or Advisory Boards: Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, ATI, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Cefaly, Charleston Labs, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Sudler and Hennessey, Supernus, Teva, Theranica, Trinity Partners, XOC, Zosano.
Salary: Dartmouth-Hitchcock Medical Center, American Headache Society.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!